e-Drug3D

623

GANCICLOVIR


INN
GANCICLOVIR

(is an active metabolite) (has an active metabolite)

cas 82410-32-0
CLASS

ANTIINFECTIVES
ANTIVIRAL
CYTOMEGALOVIRUS (CMV)
HERPES SIMPLEX VIRUS (HSV)
ACYCLIC NUCLEOSIDE ANALOGUE OF 2'-DEOXYGUANOSINE

ROUTE (list)

INJECTION ORAL IMPLANTATION OPHTHALMIC INTRAVENOUS

ATC code

J05AB06
S01AD09

PK parameters

Tmax 2 HOUR
VD 45.7 LITER (65 KILOGRAM)
Cl 11.9 LITER / HOUR
PPB 1 PERCENT
t1/2 3.81 HOUR

Solubility

APPROXIMATELY 6 MILLIGRAM / MILLILITER AT 37 DEGREE CELSIUS


Target

TARGET THYMIDINE KINASE

PDB
1KI2 (THYMIDINE KINASE FROM HERPES SIMPLEX VIRUS TYPE I)

Ligand code = GA2 (link to the list of PDB complexes)

Download experimental 3D coordinates of GA2 with added hydrogens

DrugCentral

DNA polymerase catalytic subunit UNIPROT P04293

Download SDF file 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one

Formula:
C9H13N5O4

Calculated chemical properties:

MW 255.24
NB_atoms 18
XLogP -1.97
PSA 128.967
NB_HD 5
NB_HA 9
fsp3 0.44
Lipinski(0=no;1=yes) 1

FDA
NDA 076457 (pdf not found) INN (GANCICLOVIR) GANCICLOVIR (RANBAXY LABS LTD) APPROVAL= - YEAR= 0 DISCONTINUED
NDA 019661 (label) INN (GANCICLOVIR SODIUM) CYTOVENE (CHEPLAPHARM) APPROVAL= AP YEAR= 1989 DISCONTINUED
NDA 020460 (pdf not found) INN (GANCICLOVIR) CYTOVENE (ROCHE PALO) APPROVAL= AP YEAR= 1994 DISCONTINUED
NDA 020569 (pdf not found) INN (GANCICLOVIR) VITRASERT (BAUSCH AND LOMB) APPROVAL= AP YEAR= 1996 DISCONTINUED
NDA 076222 (pdf not found) INN (GANCICLOVIR SODIUM) GANCICLOVIR SODIUM (HIKMA) APPROVAL= AP YEAR= 2003
NDA 022211 (label) INN (GANCICLOVIR) ZIRGAN (BAUSCH AND LOMB) APPROVAL= AP YEAR= 2009
NDA 090658 (pdf not found) INN (GANCICLOVIR SODIUM) GANCICLOVIR SODIUM (FRESENIUS KABI USA) APPROVAL= AP YEAR= 2010
NDA 202624 (pdf not found) INN (GANCICLOVIR SODIUM) GANCICLOVIR SODIUM (AM REGENT) APPROVAL= AP YEAR= 2013 DISCONTINUED
NDA 204950 (pdf not found) INN (GANCICLOVIR SODIUM) GANCICLOVIR SODIUM (PH HEALTH) APPROVAL= AP YEAR= 2016
NDA 209347 (label) INN (GANCICLOVIR) GANZYK-RTU (EXELA PHARMA) APPROVAL= AP YEAR= 2017 DISCONTINUED
NDA 204560 (pdf not found) INN (GANCICLOVIR SODIUM) GANCICLOVIR SODIUM (ONESOURCE SPECIALTY) APPROVAL= AP YEAR= 2017 DISCONTINUED
NDA 207645 (pdf not found) INN (GANCICLOVIR SODIUM) GANCICLOVIR SODIUM (PHARMASCIENCE INC) APPROVAL= AP YEAR= 2017
NDA 204204 (pdf not found) INN (GANCICLOVIR SODIUM) GANCICLOVIR SODIUM (SLATE RUN PHARMA) APPROVAL= AP YEAR= 2018
NDA 212001 (pdf not found) INN (GANCICLOVIR SODIUM) GANCICLOVIR SODIUM (CUSTOPHARM INC) APPROVAL= AP YEAR= 2019 DISCONTINUED

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL

e-Drug3D

1645

M GANCICLOVIR


INN
GANCICLOVIR

(is an active metabolite)

cas 86761-38-8
CLASS

ANTIINFECTIVES
ANTIVIRAL
CYTOMEGALOVIRUS (CMV)
HERPES SIMPLEX VIRUS (HSV)
COMPETITIVE INHIBITION OF VIRAL DNA POLYMERASES
INCORPORATION INTO VIRAL DNA RESULTING IN EVENTUAL TERMINATION OF VIRAL DNA ELONGATION
NUCLEOSIDE ANALOGUE

ROUTE (list)

-

ATC code

J05AB06
S01AD09

PK parameters

Target

-

DrugCentral

DNA polymerase catalytic subunit UNIPROT P04293

Download SDF file Triphosphoric acid, P-[2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl] ester

Formula:
C9H16N5O13P3

Calculated chemical properties:

MW 491.15
NB_atoms 30
XLogP -4.15
PSA 259.307
NB_HD 4
NB_HA 18
fsp3 0.44
Lipinski(0=no;1=yes) 0

FDA
-

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL

e-Drug3D

1646

M GANCICLOVIR


INN
GANCICLOVIR

(is an active metabolite)

cas 86761-38-8
CLASS

ANTIINFECTIVES
ANTIVIRAL
CYTOMEGALOVIRUS (CMV)
HERPES SIMPLEX VIRUS (HSV)
COMPETITIVE INHIBITION OF VIRAL DNA POLYMERASES
INCORPORATION INTO VIRAL DNA RESULTING IN EVENTUAL TERMINATION OF VIRAL DNA ELONGATION
NUCLEOSIDE ANALOGUE

ROUTE (list)

-

ATC code

J05AB06
S01AD09

PK parameters

Target

-

PDB
7AOM (STRUCTURE OF NUDT15 IN COMPLEX WITH GANCICLOVIR TRIPHOSPHATE)

Ligand code = RQ2 (link to the list of PDB complexes)

Download experimental 3D coordinates of RQ2 with added hydrogens

DrugCentral

DNA polymerase catalytic subunit UNIPROT P04293

Download SDF file Triphosphoric acid, P-[2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl] ester

Formula:
C9H16N5O13P3

Calculated chemical properties:

MW 491.15
NB_atoms 30
XLogP -4.15
PSA 259.746
NB_HD 4
NB_HA 18
fsp3 0.44
Lipinski(0=no;1=yes) 0

FDA
-

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL